NPPB and heart failure: Another study, Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure (DAPA-HF), included 4744 patients with heart failure with or without T2DM, reduced EF (≤40%), NYHA score II–IV, and elevated NT-proBNP.